Molecular basis for decreased folylpoly-γ-glutamate synthetase expression in a methotrexate resistant CCRF-CEM mutant cell line

Leukemia Research

Volumn 31, Issue 3, 2007, Pages 293-299

  Leclerc, Guy J ^a   York, Teresa A ^b   Hsieh Kinser, Tingting ^a   Barredo, Julio C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

CCRF CEM; Folate; FPGS; Leukemia; Methotrexate resistance; Mutagenesis; Mutant; Point mutation; SLC19A1; T ALL

Indexed keywords

AMINO ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; NUCLEOTIDE;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL MUTANT; CONTROLLED STUDY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, T-CELL, ACUTE; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE SYNTHASES; POINT MUTATION; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846063408     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.016     Document Type: Article

References (22)

1. Niemeyer C.M., Hitchcock-Bryan S., and Sallan S.E. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 12 (1985) 122-130
2. McGuire J.J., and Bertino J.R. Enzymatic synthesis and function of folylpolyglutamates. Mol Cell Biochem 38 (1981) 19-48 Spec no
3. McGuire J.J., Hsieh P., Coward J.K., and Bertino J.R. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 255 (1980) 5776-5788
4. Moran R.G., Colman P.D., Rosowsky A., Forsch R.A., and Chan K.K. Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetase. Mol Pharmacol 27 (1985) 156-166
5. Chen L., Qi H., Korenberg J., Garrow T.A., Choi Y.J., and Shane B. Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J Biol Chem 271 (1996) 13077-13087
6. Freemantle S.J., Taylor S.M., Krystal G., and Moran R.G. Upstream organization of and multiple transcripts from the human folylpoly-gamma-glutamate synthetase gene. J Biol Chem 270 (1995) 9579-9584
7. Leclerc G.J., and Barredo J.C. Folylpoly-gamma-glutamate synthetase gene mRNA splice variants and protein expression in primary human leukemia cells, cell lines, and normal human tissues. Clin Cancer Res 7 (2001) 942-951
8. Freemantle S.J., and Moran R.G. Transcription of the human folylpoly-gamma-glutamate synthetase gene. J Biol Chem 272 (1997) 25373-25379
9. Zhao R., Titus S., Gao F., Moran R.G., and Goldman I.D. Molecular analysis of murine leukemia cell lines resistant to 5,10-dideazatetrahydrofolate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 275 (2000) 26599-26606
10. Pizzorno G., Mini E., Coronnello M., McGuire J.J., Moroson B.A., Cashmore A.R., et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 48 (1988) 2149-2155
11. McGuire J.J., Haile W.H., Russell C.A., Galvin J.M., and Shane B. Evolution of drug resistance in CCRF-CEM human leukemia cells selected by intermittent methotrexate exposure. Oncol Res 7 (1995) 535-543
12. McBurney M.W., and Whitmore G.F. Characterization of a Chinese hamster cell with a temperature-sensitive mutation in folate metabolism. Cell 2 (1974) 183-188
13. Zhang L., Taub J.W., Williamson M., Wong S.C., Hukku B., Pullen J., et al. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 4 (1998) 2169-2177
14. Leclerc G.J., Leclerc G.M., and Barredo J.C. Real-time RT-PCR analysis of mRNA decay: half-life of Beta-actin mRNA in human leukemia CCRF-CEM and Nalm-6 cell lines. Cancer Cell Int 2 (2002) 1
15. Antonsson B., Barredo J., and Moran R.G. A microassay for mammalian folylpolyglutamate synthetase. Anal Biochem 186 (1990) 8-13
16. Levitt M. Accurate modeling of protein conformation by automatic segment matching. J Mol Biol 226 (1992) 507-533
17. Thompson J.D., Higgins D.G., and Gibson T.J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22 (1994) 4673-4680
18. McCloskey D.E., McGuire J.J., Russell C.A., Rowan B.G., Bertino J.R., Pizzorno G., et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266 (1991) 6181-6187
19. Sheng Y., Cross J.A., Shen Y., Smith C.A., and Bognar A.L. Mutation of an essential glutamate residue in folylpolyglutamate synthetase and activation of the enzyme by pteroate binding. Arch Biochem Biophys 402 (2002) 94-103
20. Sanghani S.P., Sanghani P.C., and Moran R.G. Identification of three key active site residues in the C-terminal domain of human recombinant folylpoly-gamma-glutamate synthetase by site-directed mutagenesis. J Biol Chem 274 (1999) 27018-27027
21. Sun X., Bognar A.L., Baker E.N., and Smith C.A. Structural homologies with ATP- and folate-binding enzymes in the crystal structure of folylpolyglutamate synthetase. Proc Natl Acad Sci USA 95 (1998) 6647-6652
22. Liani E., Rothem L., Bunni M.A., Smith C.A., Jansen G., and Assaraf Y.G. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 103 (2003) 587-599